3 Contract Drug Development and Manufacturing Company, Branded Medicines Maker and Fluorospecialty Chemicals Group Stocks With a Strong Future Roadmap: Anthem Biosciences, Torrent Pharmaceuticals and SRF

Contract pharma, branded drug and fluoro stocks offer a focused view of a sector where demand keeps widening. Anthem Biosciences, Torrent Pharmaceuticals and SRF cover a contract drug development and manufacturing company, a branded medicines maker and a fluorospecialty chemicals group.

This list covers three contract pharma, branded drug and fluoro stocks with complete current figures: Anthem Biosciences, Torrent Pharmaceuticals and SRF. Every figure comes from the latest reported financials and the 29 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Contract Pharma, Branded Drug and Fluoro Stocks?

Contract pharma, branded drug and fluoro stocks are listed companies that serve global pharma and biotech firms with development and manufacturing, sell central nervous system and gastro intestinal medicines and produce refrigerant gases, fluorospecialty chemicals and packaging films. Their earnings depend on orders, prescriptions and product mix.

Contract Pharma, Branded Drug and Fluoro Stocks at a Glance

On valuation, SRF trades at a P/E below the industry P/E, while Anthem Biosciences and Torrent Pharmaceuticals trade above it, which reflects the growth the market already expects. Readers comparing contract pharma, branded drug and fluoro stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Contract Pharma, Branded Drug and Fluoro Stocks Have a Strong Roadmap in India?

Contract pharma, branded drug and fluoro stocks have a strong roadmap in India because global drug makers outsourcing more work, steady chronic care demand and wider use of specialty chemistry keep widening the market for these companies.

• Outsourcing. Global pharma partners with Indian developers.
• Chronic care. Branded medicines bring repeat prescriptions.
• Specialty chemistry. Fluorochemicals serve many end uses.

Why Anthem Biosciences Features Among These Contract Pharma, Branded Drug and Fluoro Stocks

Among the contract pharma, branded drug and fluoro stocks on this list, Anthem Biosciences is a research-driven contract development and manufacturing organisation that serves global pharma and biotech customers with discovery, development and manufacturing services.

Revenue rose from Rs 1,280 crore in FY22 to Rs 2,280 crore in FY26, a compound annual growth rate of 15.5%. Net profit grew from Rs 406 crore in FY22 to Rs 592 crore in FY26, which works out to a compound annual growth rate of 9.9%.

The company has a return on equity of 19.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 45,546 crore. The stock trades at a P/E of 79.1, above the industry P/E of 36.0.

Roadmap: The company offers an integrated platform from discovery to commercial manufacturing, which makes it a partner for innovator clients. Its biologics, peptides and small-molecule services give it several routes to growth.

What to watch: Monitor the order pipeline from global customers and the ramp-up of newer manufacturing capacity.

Why Torrent Pharmaceuticals Features Among These Contract Pharma, Branded Drug and Fluoro Stocks

Among the pharma and chemicals shares on this list, Torrent Pharmaceuticals is an Ahmedabad-based pharma company that leads in cardiovascular, central nervous system and gastro-intestinal therapies in India, with a growing presence in Brazil, Germany and the United States.

The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P/E of 80.3, above the industry P/E of 36.0.

Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%. In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore.

Roadmap: The company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.

What to watch: Watch the integration of newly acquired brands and the progress of margin improvement in the enlarged business.

Why SRF Features Among These Contract Pharma, Branded Drug and Fluoro Stocks

Among the three companies on this list, SRF is a diversified chemicals and materials company with fluorospecialty chemicals, refrigerant gases, packaging films and technical textiles, with customers in India and overseas.

Revenue rose from Rs 12,549 crore in FY22 to Rs 15,894 crore in FY26, a compound annual growth rate of 6.1%. Net profit grew from Rs 1,336 crore in FY24 to Rs 1,835 crore in FY26, which works out to a compound annual growth rate of 17.2%.

The company has a return on equity of 14.9%, a debt to equity ratio of 0.35 and a market capitalisation of Rs 69,274 crore. The stock trades at a P/E of 30.4, below the industry P/E of 33.9.

Roadmap: The company is expanding in specialty chemicals and refrigerant gases while its packaging films and technical textiles businesses add scale. A mix of segments spreads earnings.

What to watch: Track specialty chemicals growth, refrigerant gas demand and capacity additions.

Anthem Biosciences vs Torrent Pharmaceuticals vs SRF on Key Financials

The table below sets the three contract pharma, branded drug and fluoro stocks side by side on revenue, profit and margin, using reported figures.

Torrent Pharmaceuticals posts the highest return on equity in this group at 25.5%. SRF has the largest FY26 revenue at Rs 15,894 crore, and Anthem Biosciences shows the fastest revenue growth with a 15.5% compound annual rate. A useful habit with contract pharma, branded drug and fluoro stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Contract Pharma, Branded Drug and Fluoro Stocks

Every theme carries risks that deserve a check before any decision. For these contract pharma, branded drug and fluoro stocks, the main points are: Long-term pharma and chemicals shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Regulatory approvals. Plant inspections and approvals can affect supplies.
• Raw material and energy costs. Input prices can move margins in chemicals.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter contract pharma, branded drug and fluoro stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Contract Pharma, Branded Drug and Fluoro Stocks

Contract pharma, branded drug and fluoro stocks reward patient research into demand, execution and financial strength. Anthem Biosciences, Torrent Pharmaceuticals and SRF each have a clear plan to grow. Based on the 29 October 2026 close, Anthem Biosciences trades at Rs 830.15, Torrent Pharmaceuticals at Rs 4,580 and SRF at Rs 2,358.6.

Download the Univest iOS App or Univest Android App to track contract pharma, branded drug and fluoro stocks, set price alerts and get research-backed stock ideas.

What are contract pharma, branded drug and fluoro stocks?

Ans. Contract pharma, branded drug and fluoro stocks are listed companies that serve global pharma and biotech firms with development and manufacturing, sell central nervous system and gastro intestinal medicines and produce refrigerant gases, fluorospecialty chemicals and packaging films. Their earnings depend on orders, prescriptions and product mix. This list looks at three of them, Anthem Biosciences, Torrent Pharmaceuticals and SRF, using reported FY22 to FY26 financials and the 29 October 2026 closing prices.

Which contract pharma, branded drug and fluoro stocks are covered in this list?

Ans. This list covers Anthem Biosciences, Torrent Pharmaceuticals and SRF. Based on the 29 October 2026 close, Anthem Biosciences traded at Rs 830.15, Torrent Pharmaceuticals at Rs 4,580 and SRF at Rs 2,358.6. Their return on equity ranges from 14.9% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 6.1% to 15.5%.

Why do contract pharma, branded drug and fluoro stocks have a strong future roadmap in India?

Ans. Contract pharma, branded drug and fluoro stocks have a strong roadmap in India because global drug makers outsourcing more work, steady chronic care demand and wider use of specialty chemistry keep widening the market for these companies. The main drivers are as follows. Outsourcing. Global pharma partners with Indian developers. Chronic care. Branded medicines bring repeat prescriptions. Specialty chemistry. Fluorochemicals serve many end uses. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Anthem Biosciences performed financially?

Ans. Revenue rose from Rs 1,280 crore in FY22 to Rs 2,280 crore in FY26, a compound annual growth rate of 15.5%. Net profit grew from Rs 406 crore in FY22 to Rs 592 crore in FY26, which works out to a compound annual growth rate of 9.9%. The company has a return on equity of 19.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 45,546 crore. The stock trades at a P/E of 79.1, above the industry P/E of 36.0. Looking ahead, the company offers an integrated platform from discovery to commercial manufacturing, which makes it a partner for innovator clients. Its biologics, peptides and small-molecule services give it several routes to growth.

How has Torrent Pharmaceuticals performed financially?

Ans. Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%. In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P/E of 80.3, above the industry P/E of 36.0. Looking ahead, the company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.

How has SRF performed financially?

Ans. Revenue rose from Rs 12,549 crore in FY22 to Rs 15,894 crore in FY26, a compound annual growth rate of 6.1%. Net profit grew from Rs 1,336 crore in FY24 to Rs 1,835 crore in FY26, which works out to a compound annual growth rate of 17.2%. The company has a return on equity of 14.9%, a debt to equity ratio of 0.35 and a market capitalisation of Rs 69,274 crore. The stock trades at a P/E of 30.4, below the industry P/E of 33.9. Looking ahead, the company is expanding in specialty chemicals and refrigerant gases while its packaging films and technical textiles businesses add scale. A mix of segments spreads earnings.

What risks should investors check before buying contract pharma, branded drug and fluoro stocks?

Ans. Investors should check a few risks before buying contract pharma, branded drug and fluoro stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Raw material and energy costs. Input prices can move margins in chemicals. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of contract pharma, branded drug and fluoro stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 29 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.